Janis (49 years old)

Janis, 49 years old, was diagnosed with de novo HR- HER2+ MBC some years ago. Today, she comes to the clinic for her seventh infusion of trastuzumab deruxtecan. She has no complaints.

Assessment summary

• Premenopausal
• No relevant comorbidities
• ECOG PS: 1
• Medical history:
  • Diagnosis de novo HR- HER2+ MBC
  • Tumour biology (breast lesion): invasive ductal carcinoma, ER 0%, PgR 0%, HER2 IHC 3+
  • First-line treatment for bone and lung metastases:
    • Docetaxel + trastuzumab-pertuzumab for 8 cycles
    • Maintenance dual blockade (trastuzumab-pertuzumab for 18 months)
  • Second-line treatment for multiple bone progression:
    • Trastuzumab deruxtecan for 6 cycles with partial response documented after 4 cycles
• Patient had a systematic CT scan before her seventh infusion: non-specific interstitial lung disease (ILD) grade 1